Arthritis Treatment Eases Signs of Inflammation in ALS Patients in Trial

Arthritis Treatment Eases Signs of Inflammation in ALS Patients in Trial

301889

Arthritis Treatment Eases Signs of Inflammation in ALS Patients in Trial

Actemra (tocilizumab), an approved treatment for rheumatoid arthritis, was found to be safe and well-tolerated, and to reduce a key marker of inflammation in amyotrophic lateral sclerosis (ALS) patients with evidence of systemic inflammation in a Phase 2 study. Trial results did not demonstrate that Actemra could slow ALS disability progression. But this study in 22 people “was not originally powered to detect clinical effect,” its researchers wrote, and a larger “efficacy trial” is warranted. Findings for…

You must be logged in to read/download the full post.